Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | GRN | P28799 | 1/20 | 0.39 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 9/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CTSS | P25774 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18762450 | 0.79 | GRN (0.58) | NAALAD2TSHRGRNSORT1ALDH1A1 | |
| SCHEMBL18762452 | 0.79 | GRN (0.58) | NAALAD2TSHRGRNSORT1ALDH1A1 | |
| SCHEMBL17021876 | 0.79 | TSHR (0.41) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL17021897 | 0.78 | GHSR (0.41) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL29677972 | 0.77 | NAALAD2 (0.69) | NAALAD2TSHRGRNSORT1ALDH1A1 | |
| SCHEMBL17021889 | 0.77 | TSHR (0.40) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL17021888 | 0.74 | TSHR (0.41) | TSHRALDH1A1L3MBTL1LMNACTSK | |
| SCHEMBL24058755 | 0.74 | TSHR (0.38) | PLA2G2CTSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL20057137 | 0.74 | TSHR (0.38) | PLA2G2CTSHRALDH1A1L3MBTL1LMNA | |
| SCHEMBL20204233 | 0.74 | PIN1 (0.57) | TSHRALDH1A1LMNACTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278968-B2 | Imidazopyridine compounds | ASTELLAS PHARMA INC. (JP) | 2016-03-08 | — | — | US | disclosed |
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232464-A1 | IMIDAZOPYRIDINE COMPOUNDS | PRKG1, PDE3B, PDE3A | PLA2G2C 682/4885NAALAD2 2245/4885TSHR 4263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.